Agenda

17 September 2020,
DoubleTree Tower of London

Agenda

HSJ National Cardio Forum

17 September 2020 | DoubleTree Tower of London

Draft Programme

Enacting sustainable system-wide change to cardiovascular care

09.00 Registration & Refreshments
10.00 Chair’s Opening Remarks
10.15

Panel Discussion:
Assessing the impact of COVID-19 on national stroke and cardiovascular plans

  • Responding to the impact of the pandemic and taking forward learning on admissions and service provision
  • Understand the longer term effects for cardiovascular care delivery in the NHS
  • How the NHS can get back on track with delivering the long term plan following COVID-19
11.30 Morning Refreshments & Networking
11.45

Interactive Discussion Groups:

Join these intimate and focused small-group discussions to share experiences with senior colleagues and get your pressing questions answered. With tables limited to just 12 participants, ensure you sign up early to ensure your place at your preferred two tables.

Making the case for commissioning cardiac rehabilitation

Empowering patients to understand and manage their hypertension

Using Quality Improvement methodology to redesign services

Achieving your local aims through collaboration

Establishing workforce as the driver of sustainable change

Using the data available to underpin action on managing clinical risk factors​

12.45 Networking Lunch
13.45

Session A: Providing holistic management for CVD patients during a pandemic

  • Understand how many patients with high-risk conditions are potentially undiagnosed, under treated or over treated and how to use this information
  • How can the NHS minimise the number of must-attend appointments for patients with multiple conditions?
  • Explore how to establish a one stop option for patients with high risk cardiac conditions and multimorbidities

Session reserved for Bayer

Session B: Reducing hospital waiting times after the restoration of services

  • Examine the impact of coronavirus on hospital admissions for cardiovascular patients
  • Understand the mid and long term issues and how to approach the challenge 
  • Address waiting times specifically and potential solutions
14.25 Session Change
14.30

Session A: Effective management and treatment of Familial Hypercholesterolaemia (FH)

  • Learn more about plans to expand genetic testing to identify at least 25% of those with FH
  • Identify and address gaps in your FH service
  • Explore successful examples for managing those diagnosed with FH

 

Session B: Reducing the burden and societal costs of stroke

  • Find out how the NHS is progressing with plans to roll out post-hospital stroke rehabilitation models
  • How a whole system approach to reducing the numbers of people having strokes could reduce pressure on social care
  • Hear about approaches to prevention and rehabilitation and how they have been successfully implemented
15.10 Afternoon Refreshments & Networking
15.25

Session A: Opportunities for the use of AI in CVD prevention and management

  • Learn about the potential opportunities of using AI and machine learning to identify patients at risk of Atrial Fibrillation
  • Understand how AI could be used to change the way in which patients are communicated with
  • Hear specific examples, and consider how you could implement machine learning approaches 

 

Session B: Using remote monitoring to support vulnerable patients

  • Discuss what the increased use of remote monitoring during coronavirus means for the longer term
  • Understand the key takeaways from using remote monitoring through necessity and how the benefits can continue
  • Learn from those who have successfully increased remote monitoring during the pandemic and their plans for the future
16.05 Session Change
16.10

Panel Discussion:
Creating a sustainable, whole system approach to CVD prevention

  • Identify the enabling factors to ensure change happens and is sustainable
  • Activate and involve all stakeholders to work towards preventing 150,000 heart attacks, strokes and dementia cases
  • Build a workforce that is competent, confident and enthused to continue CVD prevention work at scale and beyond pilots
17.00 Chair’s Closing Remarks

 

Copyright© 2020 Wilmington plc This programme is a draft, Health Service Journal, part of Wilmington plc, reserves the right to alter the venue and/or speakers at any time.

Wilmington/ HSJ are pleased to have worked with Bayer on the development of the agenda. Bayer has provided funding for this meeting and is sponsoring presentations clearly outlined in the programme. A Bayer employee will be delivering a presentation at this meeting.

Public Sector Registration

Medical directors and associate medical directors; Clinical directors and consultant cardiologists from secondary providers; Clinical chairs and directors of commissioning from CCGs; Clinical leads and clinical directors from STPs/ICSs; Executive directors and clinical leads from GP Federations and Primary Care Networks; GPs, community pharmacists, community nurses and practice nurses; Very senior managers from arms’ length bodies including NHS England and NHS Improvement; Leaders in public health from local authorities - register your free place here

Private Sector Partnerships 

Please contact Paul Rowe to understand how you can be part of the Forum or download our brochure here

Download Programme

 

Register

000000
ffffff

By continuing to use the site you agree to our cookies policy. Accept